ASH Clinical News December 2015 | Page 7

VOLUME 01 | NUMBER 12 | DECEMBER 2015 Around the Network IN THIS ISSUE AMERICAN SOCIETY OF HEMATOLOGY HEADQUARTERS 2021 L Street NW, Suite 900 Washington, DC 20036 www.hematology.org Tel: [phone] EDITOR-IN-CHIEF Mikkael Sekeres, MD, MS Vice-Chair for Clinical Research Director, Leukemia Program Cleveland Clinic, Taussig Cancer Institute Cleveland, OH ASSOCIATE EDITORS Beth Faiman, CNP, PhD Cleveland Clinic Cleveland, OH Alice Ma, MD University of North Carolina School of Medicine Chapel Hill, NC David Steensma, MD Dana-Farber Cancer Institute Boston, MA Keith Stewart, MBChB, MBA Mayo Clinic Scottsdale, AZ PUBLISHER American Medical Communications EDITORIAL MANAGING EDITORS Ariel Jones-DeMaio, AMC Karen Learner, ASH ART DIRECTOR Ari Mihos ASSISTANT ART DIRECTOR Charlene DePrizio DIGITAL PROJECTS MANAGER Chris Gedikli ADVERTISING ACCOUNT MANAGER Nick Luciano [email protected] Gene Conselyea [email protected] Recruitment advertising orders can be sent to: DIRECTOR, RECRUITMENT CLASSIFIEDS Lauren Morgan [email protected] Visit us at ashclinicalnews.org Follow us on Twitter @ASHClinicalNews ©2015 by the American Society of Hematology. All materials contained in this newsletter are protected by copyright laws and may not be used, reproduced, or otherwise exploited in any manner without the express prior written permission of ASH Clinical News. Any third-party materials communicated to ASH Clinical News become its copyrighted property and may be used, reproduced, or otherwise exploited by ASH Clinical News. ASHClinicalNews.org Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines? Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these devices is unclear, due to the potential complications of filter placement and retrieval. In Drawing First Blood, Joseph M. Stavas, MD, and Anita Rajasekhar, MD, debate whether inferior vena cava (IVC) filters are still a viable option for managing thrombosis, particularly in the era of novel oral anticoagulants. 92 Maintenance of Credibility Two years after changing its Maintenance of Certification requirements, the American Board of Internal Medicine is still working to address concerns about the program, recently releasing its own evaluation of the program through the Assessment 2020 Task Force. We spoke with physicians involved with ABIM and MOC about the Task Force’s recommendations – what it gets right and where there is still work to be done. 100 features 22 Research Nurses: The Glue that Holds Everything Together 44 FCR in Patients with IGHV-Mutated CLL: Long-Term Remissions, Long-Term Survival 104 Palliative Care: Time for Hematology to Step Up ASHCLINICALNEWS.ORG @ASHCLINICALNEWS With more than 4,500 abstracts and over 150 sessions, the